CARL-JOHAN DALSGAARD

Carl-Johan Dalsgaard is a distinguished Venture Partner at HealthCap, a prominent European venture capital firm exclusively focused on the life science sector. In this pivotal role, Carl-Johan contributes his profound scientific and commercial expertise to identify, evaluate, and nurture groundbreaking companies that are poised to revolutionize healthcare. His involvement is crucial in guiding portfolio companies through critical development stages, from early-stage research to clinical trials and market entry.

HealthCap, under the guidance of partners like Carl-Johan Dalsgaard, invests in a broad spectrum of life science innovations. Carl-Johan's specific investment focus areas align with HealthCap's mission to back companies developing novel therapeutics, diagnostics, and medical technologies. He is particularly interested in biotechnology and pharmaceutical ventures that address significant unmet medical needs, leveraging his deep understanding of drug discovery and development processes.

Carl-Johan's extensive career background provides a robust foundation for his role at HealthCap. Prior to joining the firm, he held several leadership positions that honed his strategic and operational skills in the pharmaceutical industry. Notably, he served as CEO of Pila Pharma and CEO of Action Pharma, where he was instrumental in advancing drug candidates through various development phases. His career also includes a significant tenure at Novo Nordisk, a global healthcare company, where he held various senior executive roles, including Corporate Vice President and Senior Vice President. These roles provided him with invaluable experience in global drug development, clinical operations, and commercial strategy across multiple therapeutic areas.

Educated as an MD and holding a PhD in Medical Sciences from the University of Copenhagen, Carl-Johan Dalsgaard combines a strong scientific background with practical business acumen. This unique blend allows him to critically assess the scientific merit of potential investments while also understanding the commercial viability and market potential. While specific notable investments directly led by Carl-Johan are often part of HealthCap's collective portfolio success, his expertise is vital in shaping the firm's investment decisions and providing strategic guidance to its portfolio companies, helping them navigate the complex landscape of drug development and market access. His contributions ensure that HealthCap continues to back companies with the potential to deliver significant patient benefits and strong financial returns.